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considerably more sensitive to F. tularensis infection (33) and, therefore, we purposefully 135 decided to optimize our vaccine in female mice first. 136
Immunizations and challenges. Mice were immunized twice, two weeks apart (day 0 137 and day 14), by i.p. or by s.c. injection with empty vesicles (V) or vesicles in which F. 138 tularensis LVS components were incorporated (LVS-V; 35 µg protein/mouse), without or 139 with the addition of 100 μg MPL to the LVS-V immediately prior to immunization. For 140 i.n. booster vaccine, V or LVS-V (10 µg protein/mouse), without or with addition of 10 141 μg/mouse of MPL, was administered in a split volume of 25 μL in each nare. Pre-142 challenge sera were collected one day prior to bacterial challenge and frozen until further 143 use. Mice were challenged i.n. with live F. tularensis LVS (~5,000 CFU/mouse) or with 144 F. tularensis Schu S4 (~20 CFU/mouse), diluted in 25 µL sterile saline. Mice were 145 observed twice daily for tularemia symptoms for at least two weeks following bacterial 146 challenge. All F. tularensis LVS challenges were carried out at UMB under an IACUC 147 protocol that allowed us to observe the mice with early tularemia symptoms to see if they 148 would recover, and moribund mice were euthanized. All F. tularensis Schu S4 challenges 149 were carried out in the UVA ABSL-3 facility, and since disease progression in F. 150 tularensis Schu S4 infected mice can proceed rapidly and recovery is quite rare, the 151 IACUC protocol for these challenges requires euthanization of mice at first clinical signs 152 of tularemia disease. 153
For passive immunization experiments, pre-challenge sera from each group of 154 immunized mice were pooled and 50 µL administered to naïve 6-8 week old female 155 C57BL/6J mice by i.v. injection one day prior to challenge. Mice were challenged by s.c. Clinical scores were assigned as follows: 0, healthy appearance; 1, reduced 160 activity and/or weight loss; 2, symptoms of '1' + piloerection; 3, symptoms of '2' + 161 hunched posture; 4, symptoms of '3' + severely reduced activity. Score '5' was used to 162 tally animals that were moribund and had to be euthanized or were found dead. Mice in 163 the ABSL-3 facility are euthanized at the first sign of disease, typically with a clinical 164 score of "1." 165 ELISA and Western blot analysis. Sera were harvested from mice immunized by 166 various protocols at the indicated time points. Bronchoalveolar lavage fluid (BALf) was 167 harvested in 1 mL sterile PBS from euthanized mice on day 7 after i.p./i.n. immunizations. 168
F. tularensis-specific antibody titers were determined by ELISA on plates coated with 169 whole F. tularensis LVS, using HRP-conjugated secondary antibodies (goat anti-mouse 170
IgA, goat anti-mouse IgM, or a pool of goat anti-mouse IgG1, IgG2b, IgG2c, and IgG3; 171 all human-adsorbed and purchased from Southern Biotech, Birmingham, AL) and the 172 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS; Sigma) 173 reaction in 0.05 M Phosphate-Citrate buffer (Sigma) for detection as previously described 174 (25, 34, 35). IFN-γ ELISA on cell culture supernatants was carried out by the Cytokine 175
Core Facility at University of Maryland, Baltimore (UMB). 176
Sera from V + MPL, LVS-V, and LVS-V + MPL-immunized mice were also 177 analyzed by Western blot as previously described (25). Briefly, to approximate equal 178 loading per lane, overnight cultures of F. tularensis strains Schu S4, MA00, OR96, and 179 LVS were diluted to OD 600 of 0.30 prior to pelleting 20 mL of bacteria. Bacterial pellets 180 on October 29, 2017 by guest http://cvi.asm.org/ Downloaded from 9 were lysed in 1 mL Laemmli sample buffer. These lysates were boiled for 10 min and 181 were separated by SDS-PAGE (10 μL/well) on 12% Tris-Glycine (TGX) gels (Bio-Rad, 182
Hercules, CA) in triplicate and transferred to membrane (Millipore, Billerica, MA). Cut 183 sections of the membrane were subjected to Western analysis with pooled sera 184
(1:100,000 dilution) from immunized mice two weeks after the second immunization (i.e., 185 pre-challenge). Detection was achieved using the same secondary antibodies as for the 186 ELISA, followed by reaction with ECL Plus (Pierce, Rockford, IL). Western blots were 187 imaged on X-ray film (GE Healthcare Limited, Little Chalfont, UK). bands at ~20 kDa, ~37 kDa (detected more strongly by LVS-V sera), ~45 kDa, and ~100 376 kDa (detected more strongly by LVS-V + MPL sera) ( Figure 3D , left blots). In blots 377 developed using sera from mice immunized with LVS-V alone, few additional antigens 378 were detected after overnight exposure (data not shown). In contrast, secondary anti-IgG Figure 3D, right blots) . In our hands, BALf IgA from any immunization group 385 failed to detect purified F. tularensis LPS (data not shown). 386
Enhanced cellular response to F. tularensis after LVS-V + MPL immunization. 387
Cellular immune responses have been shown to be critical for controlling F. tularensis 388
infection. In particular, the ability of T cells to produce IFN-γ has been reported to be a 389 strong correlate of protection in mice (36, 43, 44). We measured IFN-γ production in four 390 separate experiments, two where the splenocyte donor mice had been immunized by 391 homologous (i.p./i.p.) route of immunization, as described in Figure 1 , and two where the 392 splenocyte donor mice had been immunized by heterologous (i.p./i.n.) route of 393 immunization, as described in Figure 3 . Two weeks after final immunization, 394 splenocytes were harvested from naïve mice or mice that had been immunized with V + 395 MPL, LVS-V, or LVS-V + MPL, and these cells were co-cultured with F. tularensis 396 LVS-infected bone marrow-derived macrophages (BMDM), as described (36, 37). After 397 72 h of co-culture, the non-adherent cells were analyzed by flow cytometry, using a 398 gating strategy for discriminating subsets of T cells (Supplemental Fig. 1 ). Activated 
Effects of LVS-V ± MPL immunization against i.n. F. tularensis Schu S4 challenge. 419
We previously elicited partial protection against i.n. challenge with F. tularensis Schu S4 420 by using a heterologous i.p./i.n. immunization regimen (25). Therefore, we next sought to 421 assess whether protection gained by immunizing mice by these heterologous routes 422 would be further increased by adjuvanting LVS-V vaccine with MPL. Mice were 423 immunized i.p./i.n., as described above. On day 28, mice were challenged i.n. with ~20 424 CFU F. tularensis Schu S4. Consistent with our previous studies, 9 of 10 mice that were 425 Although this was not the primary goal of our study to compare mouse models of 527 tularemia, this study also revealed other possible differences based on animal protocols 528 and challenge strains used. Most notably, we only observed the intrinsic adjuvant activity 529 of V in F. tularensis LVS challenge using an animal model that only euthanizes 530 moribund mice, thus allowing time for sick mice to recover. The F. tularensis Schu S4 531 challenge model, however, is more stringent and is better for assessing vaccine efficacy. 532
In conclusion, F. tularensis is a highly virulent pathogen for which no licensed 533 vaccine exists in the USA. Effective subunit vaccines against this pathogen are difficult 534 to achieve (57, 58). The LVS-V + MPL subunit vaccine, that enhances both B and T cell 535 adaptive immune responses and confers 60% survival after i.n. challenge with F. 536 tularensis Schu S4, represents a significant step forward in the development of a safe 537 subunit vaccine for protecting against this potential biothreat agent. We will continue to 538 optimize this vaccine in other animal models of tularemia with the goal of providing full 539 protection against this important pathogen. 540
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